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Abstract
Background: This systematic review with meta-analysis was designed to evaluate the literature
and to develop recommendations regarding the use of preoperative radiotherapy in the
management of patients with resectable rectal cancer.
Methods: The MEDLINE, CANCERLIT and Cochrane Library databases, and abstracts published
in the annual proceedings of the American Society of Clinical Oncology and the American Society
for Therapeutic Radiology and Oncology were systematically searched for evidence. Relevant
reports were reviewed by four members of the Gastrointestinal Cancer Disease Site Group and
the references from these reports were searched for additional trials. External review by Ontario
practitioners was obtained through a mailed survey. Final approval of the practice guideline report
was obtained from the Practice Guidelines Coordinating Committee.
Results: Two meta-analyses of preoperative radiotherapy versus surgery alone, nineteen trials
that compared preoperative radiotherapy plus surgery to surgery alone, and five trials that
compared preoperative radiotherapy to alternative treatments were obtained. Randomized trials
demonstrate that preoperative radiotherapy followed by surgery is significantly more effective than
surgery alone in preventing local recurrence in patients with resectable rectal cancer and it may
also improve survival. A single trial, using surgery with total mesorectal excision, has shown similar
benefits in local recurrence.
Conclusion: For adult patients with clinically resectable rectal cancer we conclude that:
• Preoperative radiotherapy is an acceptable alternative to the previous practice of postoperative
radiotherapy for patients with stage II and III resectable rectal cancer;
• Both preoperative and postoperative radiotherapy decrease local recurrence but neither 
improves survival as much as postoperative radiotherapy combined with chemotherapy. Therefore, 
if preoperative radiotherapy is used, chemotherapy should be added postoperatively to at least 
patients with stage III disease.
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Background
Adenocarcinoma of the rectum is a common malignancy
that originates in the last 15 cm of the large bowel where
most of its external surface is not covered by peritoneum
but rather is directly surrounded by connective-adipose
tissue. Resection of the rectum and surrounding tissues
can cure approximately 50% of patients. The other half
will eventually die of the disease. Surgical failure is related
to distant micro metastases that are not apparent and / or
incomplete local resection. Local recurrences increase in
frequency and survival decreases as the tumor penetrates
through the rectal wall and extends to regional lymph
nodes [1]. These prognostic factors form the basis for the
tumor, node, metastases (TNM) staging system widely
used to advise therapy (see Additional file 1).
Meticulous dissection of perirectal tissues en bloc with
total mesorectal excision (TME) decreases local relapse
[2]. Preoperative and postoperative radiotherapy (RT) has
also been used to reduce local recurrence, which is associ-
ated with pelvic pain and rectal obstruction, and to pre-
vent disease dissemination from the local site, thereby
improving survival. Other goals of RT are to convert inop-
erable tumors into resectable cases, to preserve the anal
sphincter and to avert a colostomy [3]. The advantages
and disadvantages of preoperative and postoperative RT
have been well described [3]. The principal advantage of
postoperative RT is that it is given only to patients at high
risk of recurrence according to well-investigated prognos-
tic factors [pathological stages II and III (B2 and C)].
Major incentives for preoperative RT originate from a vari-
ety of perspectives. Biologically, a tumor with an undis-
turbed circulation and oxygenation has a better chance for
full radiation effects. Moreover, a tumor reduced in size
and with the surrounding tissues sterilized facilitates sur-
gery and reduces potential tumor dissemination. A more
practical incentive is the possibility of using an equally
effective five-day course of high dose fraction preoperative
RT instead of a 25 – 30 day standard postoperative course
of RT.
Another practice guideline by the Gastrointestinal Cancer
Disease Site Group (DSG) first developed in 1997 and
updated in 2001 reviewed the effects of postoperative RT
and / or chemotherapy in resected stage II / III rectal can-
cer [4]. This guideline recommended the combined use of
postoperative radiation and chemotherapy as the pre-
ferred treatment for resected stage II and III rectal cancer.
This combined treatment improved the local recurrence
rate by 50% and the five-year survival rate by 42%. The
same guideline discouraged the use of RT alone as adju-
vant treatment because it only decreased local recurrence
rates. For the present report, we initially reviewed only the
effect of RT given before definitive surgery on survival and
local recurrence. Following advice received from practi-
tioner feedback and from our resource group, we have
also included a discussion of preoperative RT compared
with postoperative combined RT plus chemotherapy. This
report does not consider the use of preoperative RT to con-
vert locally advanced, initially unresectable rectal cancer
into resectable cases, to preserve the anal sphincter, or to
delay the need for colostomy.
Methods
This practice guideline was developed by the Cancer Care
Ontario Practice Guidelines Initiative (CCOPGI), using
the methodology of the Practice Guidelines Development
Cycle [5]. Evidence was selected and reviewed by four
members of the CCOPGI's Gastrointestinal Cancer DSG
and methodologists. This practice guideline report is a
convenient and up-to-date source of the best available evi-
dence on preoperative RT for clinically resectable rectal
cancer, developed through systematic reviews, evidence
synthesis and input from practitioners in Ontario. Exter-
nal review by Ontario practitioners was obtained through
a mailed survey consisting of items that address the qual-
ity of the draft practice guideline report and recommenda-
tions, and whether the recommendations should serve as
a practice guideline. Final approval of the original guide-
line report was obtained from the Practice Guidelines
Coordinating Committee (PGCC).
The report is intended to promote evidence-based prac-
tice. The Practice Guidelines Initiative is editorially inde-
pendent of Cancer Care Ontario and the Ministry of
Health and Long-Term Care. The CCOPGI has a formal
standardized process to ensure the currency of each guide-
line report. This consists of periodic review and evaluation
of the scientific literature, and where appropriate, integra-
tion of this literature with the original guideline
information.
Examination of the evidence
Literature search strategy
MEDLINE (1966 to April 2003), CANCERLIT (1983 to
April 2002) and the Cochrane Library (Issue 1, 2003)
were searched with no language restrictions. "Rectal neo-
plasms" (Medical subject heading [MeSH]), "colorectal
neoplasms" (MeSH) and the text word "rectal cancer"
were combined with "radiotherapy" (MeSH) and the
following phrases used as text words: "preoperative";
"neoadjuvant"; "radiotherapy"; "radiation"; "irradiation".
These terms were then combined with the search terms for
the following study designs or publication types: practice
guidelines, meta-analyses, and randomized controlled tri-
als. The proceedings of the 1998 to 2002 annual meetings
of the American Society of Clinical Oncology (ASCO) and
the 1999 to 2002 annual meetings of the American Soci-
ety for Therapeutic Radiology and Oncology (ASTRO)
were searched for reports of new or ongoing trials. Rele-BMC Medicine 2003, 1 http://www.biomedcentral.com/1741-7015/1/1
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vant articles and abstracts were selected and reviewed and
the reference lists from these sources were searched for
additional trials. A search of personal reprint files was also
conducted.
Study selection criteria
Trials of preoperative RT in resectable rectal cancer are
characterized by multiple methodological problems
because two treatments are combined (RT and surgery) to
affect a heterogeneous condition (various populations
and stages of rectal carcinoma) and to achieve a variety of
goals (downstaging, improving resectability, decreasing
local and possibly distant recurrences and improving sur-
vival). Cummings [6] detailed many of the pitfalls that
marred early trials, including deficiencies in trial design,
eligibility criteria, treatment standardization and report-
ing of results. We used this critique to develop standard
criteria for the selection of trials of preoperative RT for rec-
tal cancer. Studies were included in this systematic review
of the evidence if they met all of the following criteria:
1. Patients were randomly assigned to preoperative RT
versus surgery alone or an alternative treatment.
2. The study population was well defined. Studies prefer-
ably included only rectal carcinoma, defined by tumors
located within 15 cm of the pectinate line or anal verge on
sigmoidoscopy, or rectosigmoid tumors. Patients were
screened for metastases and co-morbidity by clinical and
imaging procedures and were assessed as surgically resect-
able for cure.
3. Treatments were described clearly, including RT dose,
fractionation, duration, field size and portals of irradia-
tion. Timing of surgery after completion of RT was clearly
set. General surgical principles were described.
4. Compliance with treatments and follow-up were
described.
5. Treatment outcomes were reported for overall survival
and / or local failure. Other outcomes such as adverse
effects (morbidity and mortality), downstaging (decrease
in the proportion of cases with stage III disease), and
resectability (total and curative) were recorded if
available.
Synthesizing the evidence
Trials of preoperative RT versus surgery alone were pooled
using Review Manager 4.2.1 (© Update Software), which is
available through the Cochrane Collaboration. Overall
mortality, local failure, tumor resectability, tumor down-
staging, and adverse effects were pooled in separate anal-
yses for all studies, where data was available. Reported
figures or estimates obtained from tables or graphs were
used. For calculation of survival and local failure, all eligi-
ble patients were considered in the denominator, based
on intention to treat. All deaths at the time of reporting,
regardless of cause, were included in survival calculations.
Patients with local failure included those with non-
resected as well as those with recurrent disease. Only
resected cases were considered in the calculation of
downstaging.
Data were pooled using the random effects model as the
more conservative estimate of effect [7]. Results were
expressed as relative risk ratios (RR) with 95% confidence
intervals (CI), where a RR less than 1.0 favors preoperative
RT and a RR greater than 1.0 favors surgery alone. Odds
ratios (OR) and absolute risk differences (RD) were also
calculated.
Heterogeneity of results among trials was expected in view
of the different treatments used and populations tested, as
well as the wide time interval and geography across which
these trials were conducted. For example, the RT prescrip-
tion may affect the results. RT doses greater than 30 Gy10
are considered necessary and pelvic fields are as effective
as extended fields. Moreover, the use of three or more RT
beams will lessen toxicity and short delays of surgery after
RT will not demonstrate downstaging. Thus, these factors
were investigated with sensitivity analyses to see whether
there was an impact on results. Outcomes of predeter-
mined groups of patients were examined initially by the
graphic method described by L'Abbe et al. [8] and RR cal-
culated. For sensitivity analyses the following factors were
examined:
Treatment effects:
• Biologically effective dose (BED) of RT (less than 30
Gy10 versus equal to or greater than 30 Gy10). BED was cal-
culated using the linear quadratic formula [9] and the
parameters suggested for time correction [10]:
BED time = nd (1+d/α/β) - γ/α (T - Tk)
where n = number of fractions, d = dose per fraction, α/β
= 10 for tumor effect and acute reactions and α/β = 3 for
late reactions, γ/α = repair rate set at 0.6 Gy/day, T = total
treatment time and Tk = initial delay time set at 7 days;
• RT fraction size (standard fractions up to 2.5 Gy/day ver-
sus high fractions of 5 Gy/day);
• Contemporary RT prescription, defined as studies
employing multiple-field technique and target volume
confined to the pelvis (i.e. excluding studies employing
parallel pair arrangements or including para-aortics); andBMC Medicine 2003, 1 http://www.biomedcentral.com/1741-7015/1/1
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• Delay of surgery after completion of RT (less than seven
days versus eight or more days).
Population effects:
• Studies including a range of rectal cancer cases versus
those including only advanced disease.
Sensitivity analyses were also performed for all five of the
meta-analyses (overall survival, local failure, tumor
resectability, downstaging, and adverse effects) consider-
ing only trials with high design quality. The quality of the
14 eligible randomized trials of preoperative RT versus
surgery alone in operable rectal cancer was scored inde-
pendently. Five assessors assessed each trial using the Det-
sky instrument [11]. This questionnaire addresses five
domains of study quality: randomization process, out-
comes measure, patient eligibility, treatment description,
and statistical procedures. The 14 questions on the Detsky
instrument can be answered "adequate", "inadequate", or
"partial" and scored 1, 0, or 0.5, respectively. The final
score of each trial is a ratio of the observed points divided
by the total number of questions answered. The results
from the five assessors were averaged for a final score. Tri-
als with Detsky instrument scores greater than 0.5 were
considered to be of high quality.
Results
Literature search results
The literature search identified 24 trials. Nineteen of these
trials compared preoperative RT plus surgery to surgery
alone [12–29,38]. Five trials compared preoperative RT to
alternative treatments [30–34]. Two meta-analyses of pre-
operative RT versus surgery alone were found in a recent
search update [35,36].
Preoperative RT versus surgery alone
Four of the 19 trials of preoperative RT compared with
surgery alone were excluded from the review [12–15]. Pre-
liminary results of one trial have been reported in Russian
[12], but the report and results were difficult to interpret.
This trial was excluded until more mature results are avail-
able and it is clear that the trial meets the inclusion crite-
ria. Three trials [13–15] had major violations to the
inclusion criteria. The Memorial Hospital trial included
both randomized as well as non-randomized patients in
the analysis [13]. The Veterans Administration Surgical
Oncology Group (VASOG) Trial I included patients who
may have had apparent metastases and did not allow for
an analysis excluding this group of patients [14]. The
Essen trial was described in summary form and was a
failed trial of preoperative plus postoperative RT treat-
ment due to difficulties with compliance [15]. The
remaining 15 trials are shown in Table 1.
The significant trial coordinated by the Dutch Colorectal
Cancer Group report results after a median follow-up of
24.9 months, much shorter than other trials, and num-
bers of patients with events cannot be determined [38].
Therefore this trial is not included in the meta-analysis.
This study, which included patients with rectal cancer not
fixed or amenable to local excision, standardized surgery
with total mesorectal excision. Patients were randomized
to surgery alone or surgery preceded by RT (bottom row,
Table 1)[38]. The recurrence rate was significantly lower
in patients receiving preoperative RT (2.4% vs. 8.2%; p <
0.001) but overall survival was the same for both treat-
ment groups. In a multivariate subgroup analysis, tests for
interaction between tumor location, TNM stage and treat-
ment were not significant, suggesting that treatment effect
was similar for all the subgroups analyzed.
This left 14 trials of preoperative RT compared with sur-
gery alone [16–29]. One trial [18] contributed to two
comparisons (single fraction preoperative RT versus sur-
gery alone; multiple fractions preoperative RT versus sur-
gery alone). One trial [28] included 316 patients who
were also included in another trial [29]; neither report
described results for these patients separately from those
who were included in only one of the two trials. Reports
of three trials [17,22,23] did not provide data on compli-
ance with treatment. Where results have been reported or
updated in more than one publication, only the most
recent publication is listed.
All trials included patients with resectable rectal cancer.
Two trials also included patients with rectosigmoid
tumors [16,19]. Some trials excluded patients with small
tumors [25,28,29] or were limited to those with locally
advanced tumors [23,26,27] or those requiring abdom-
ino-perineal resection [19]. Patients excluded were those
with evidence of distant metastases, previous malignancy
or previous RT.
Surgery was performed from a few hours up to 40 days fol-
lowing the preoperative RT course, but most surgeries
were done within one to four weeks of preoperative RT.
The description of surgical procedures was very general
except for the distinction between palliative and curative
procedures. Radiation was delivered mostly by anterior
and posterior portals. Only recent trials used three or four
radiation portals [27–29]. Radiation fields were mostly
pelvic but some trials used extended guitar-shaped fields
up to L2 [16,20,21,25]. The total radiation dose and the
fractionation schedules were quite different across studies,
ranging from 5 Gy in a single treatment to over 50 Gy in
five weeks.
Compliance with treatments was generally well described.
Follow-up data were collected prospectively in all but oneBMC Medicine 2003, 1 http://www.biomedcentral.com/1741-7015/1/1
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trial [17]. The follow-up schedule was described for all tri-
als except one [16]. The rate of patients lost to follow-up
was 16% in one trial [24], but most other trials seemed to
have had greater than 90% compliance with follow-up.
The median follow-up at the time of the trial report was
five years or more in most trials.
Pooled results of trials comparing preoperative RT to 
surgery alone
Overall survival
Survival was reported for all trials except one [23]. Sur-
vival results for only resected cases were reported for one
trial [28]. The overall mortality risk ratio favored preoper-
ative RT (RR, 0.94; 95% CI, 0.89 to 0.99; p = 0.02), results
that correspond to an absolute risk difference of 4% (95%
CI, 0.7% to 7.5%; p = 0.018). There was significant heter-
ogeneity across trials (X2 = 20.59; p < 0.10). As observed
in Figure 1, most heterogeneity derived from a study from
Brazil [22]; removal of this study resulted in non-signifi-
cant heterogeneity and the results were similar (RR, 0.95;
95% CI, 0.91 to 0.99; p = 0.012). Survival benefit was
observed only for trials using BED > 30 but there was sig-
nificant heterogeneity detected.
Local failure
Local failure rate was calculated for all trials as the number
of patients unable to have tumor removal as well as those
with recurrent disease after resection. The overall relative
risk ratio favored preoperative RT (RR, 0.71; 95% CI, 0.57
to 0.89; p = 0.0025) with an absolute risk reduction of
8.6% (95% CI, 3.1% to 14.2%; p = 0.0024). There was sig-
nificant heterogeneity when local failure rates were
pooled across trials (X2 = 61.72; p < 0.001). Figure 2 dis-
plays the local failure risk ratios with the trials arranged in
ascending order of the RT dose (BED) used. There was no
treatment effect in the analysis of three trials of preopera-
tive RT using doses of 7.5 to 26.8 BED (RR, 0.95; 95% CI,
0.79 to 1.11; p = 0.58) while trials using doses greater than
or equal to 30 BED had evidence of reduced local failures
(RR, 0.63; 95% CI, 0.48 to 0.83; p = 0.0011) with signifi-
cant heterogeneity being detected.
Tumor resectability
Total tumor resectability between the treatment arms was
not significantly different when 12 trials (14 compari-
sons) involving 5 923 patients were pooled (RR, 1.00;
95% CI 0.99 to 1.00; p = 0.36). Pooling of 14 trials (16
comparisons) involving 6 816 patients detected no signif-
icant difference in curative resections for preoperative RT
compared with surgery alone (RR, 0.99; 95% CI, 0.98 to
1.01; p = 0.59). There was no significant heterogeneity
among trials in either pooled analysis.
Table 1: Randomized trials of preoperative RT versus surgery alone in resectable rectal cancer.
Trial 
(reference)
No. of patients 
randomized RT / 
no RT (analyzed)
RT prescription* Biologically 
effective 
dose (Gy10)
Compliance 
with 
RT† 0 <1 >1
Surgical 
delay after 
RT (days)
Median 
follow-up 
(months)
Study 
quality 
score‡
Yale [16] 15 (15) / 16 (16) 45 in 25 (31) 2 fields, G 53.1 - 7% - 2–42 >60 0.29
Toronto [17] 60 (60) / 65 (65) 5 in 1 (1) 2 fields, P 7.5 - - - 0 72 0.55
MRC-I [18] 549 (549) / 275 (275) 5 in 1 (1) or 20 in10 (14) 
2 fields, G
7.5 or 19.8 2% 6% - <7 >60 0.66
VASOG-II [19] 180 (180) / 181 (181) 31.5 in 18 (24) 2 fields, G 26.8 7% 11% 4% ~40 60 0.70
Norway [20] 159 (155) / 150 (145) 31.5 in 18 (24) 2 fields, G 26.8 1% - - <21 54 0.80
EORTC [21] 236 (231) / 230 (228) 34.5 in 15 (19) 2 fields, G 35.2 1% - - 1–69 >72 0.67
Brazil [22] 34 (34) / 34 (34) 40 in 20 (25) 2 fields, P 35.4 - - - 7 120 0.48
Hungary [23] 171 (171) / 165 (165) 40 in 20 (26) or 50 in 25 
(33) 2 fields, P
35.4 or 43.2 - - - 42 >60 0.44
ICRF-UK [24] 228 (228) / 239 (239) 15 in 3 (5–7) 2 fields, P 22.5 - 10% - <2 60 0.64
Stockholm-I [25] 424 (424) / 425 (425) 25 in 5 (5–7) 2 fields, G 37.5 - 12% - <7 107 0.74
MRC-II [26] 139 (139) / 140 (140) 40 in 20 (28) 2 fields, P 35.4 1% 5% 4% <7 >60 0.83
NW-UK [27] 143 (143) / 141 (141) 20 in 4 (4) 3 field, P 30.0 - 1% 3% <7 96 0.57
Sweden [28] 583 (573) / 585 (574) 25 in 5 (5) 3–4 fields, P 37.5 3% 1%§ - <7 >60 0.82
Stockholm-II [29] 272 (272) / 285 (285) 25 in 5 (5–7) 4 fields, P 37.7 -------5%------ <7 50 0.88
Dutch [38] 924 (908) / 937 (897) 25 in 5 (5) 4 fields, P 37.5 3% 2% ? <7 24.9 0.81
Note: EORTC indicates European Organization for Research and Treatment of Cancer; ICRF-UK, Imperial Cancer Research Fund United Kingdom; 
MRC, Medical Research Council; NW-UK, Northwest Region Rectal Cancer Group United Kingdom; VASOG, Veterans Administration Surgical 
Oncology Group. * Total dose in Gy, number of fractions, (duration of treatment in days), number of treatment fields, target volume (G, guitar-
shaped; P, pelvic). † 0 indicates per cent of patients receiving no treatment; <1, percent receiving less than planned treatment; >1, percent receiving 
more than planned treatment. ‡ Based on independent assessment by five reviewers using the Detsky instrument10. § 5% of patients also received RT 
over >7 days, and 8% of patients received radiation through a two portal beam.BMC Medicine 2003, 1 http://www.biomedcentral.com/1741-7015/1/1
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Downstaging
There was an overall significant decrease in the incidence
of stage III rectal cancer among patients randomized to
preoperative RT compared with surgery alone, but there
was significant heterogeneity among the pooled results
(X2 = 38.57; p < 0.001) (Figure 3). Neither radiation dose
or its fractionation, nor timing of surgery affected results.
Meta-analysis examining preoperative RT for patients with resectable rectal cancer: overall mortality Figure 1
Meta-analysis examining preoperative RT for patients with resectable rectal cancer: overall mortality. Results 
were reported for only the eligible or evaluable patients for Norway [20] trial. Results were reported for only the eligible 
patients undergoing surgery for the Sweden [28] trial.
Meta-analysis examining preoperative RT for patients with resectable rectal cancer: local failure Figure 2
Meta-analysis examining preoperative RT for patients with resectable rectal cancer: local failure. Results were 
reported for only the eligible or evaluable patients for the Norway [20] trial.BMC Medicine 2003, 1 http://www.biomedcentral.com/1741-7015/1/1
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Adverse effects
Preoperative RT did not significantly increase 30-day post-
operative mortality compared with surgery alone (RR,
1.33; 95% CI, 0.87 to 2.05; p = 0.19). These results
showed significant heterogeneity of trial results (X2  =
23.35; p < 0.05) (Figure 4). Results were not affected by
radiation dose.
Postoperative morbidity was similar across trials and con-
sisted mainly of delay of perineal wound healing and
infection. The pooled results for postoperative morbidity
also demonstrated significant heterogeneity (X2 = 62.74; p
< 0.001) (Figure 5). Results were not different for patients
receiving high or low dose RT or delay to surgery of < 7 or
> 8 days.
Meta-analysis examining preoperative RT for patients with resectable rectal cancer: incidence of stage III tumors Figure 3
Meta-analysis examining preoperative RT for patients with resectable rectal cancer: incidence of stage III 
tumors.
Meta-analysis examining preoperative RT for patients with resectable rectal cancer: 30-day postoperative mortality Figure 4
Meta-analysis examining preoperative RT for patients with resectable rectal cancer: 30-day postoperative 
mortality.BMC Medicine 2003, 1 http://www.biomedcentral.com/1741-7015/1/1
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Sensitivity analyses
Sensitivity analyses were conducted to test the robustness
of the conclusions of the five pooled analyses above (over-
all survival, local failure, tumor resectability,
downstaging, adverse effects) when excluding the three
studies with quality scores of less than 0.5 [16,22,23].
Results of the pooled analyses of the best quality studies
were not different from the results considering all studies
(data not shown). Details of the quality assessment results
using the Detsky instrument can be found in Additional
file 2.
Published meta-analyses
After completing our analysis, two literature-based meta-
analyses of trials comparing preoperative RT to surgery
alone for resectable rectal cancer were published [35,36].
The Camma et al. [35] meta-analysis followed a method-
ology similar to ours. In the analysis, however, there was
also an investigation of patient subgroups (Dukes' stages
A, B and C, and male sex) and a regression analysis for
overall survival (but not for other outcomes). The follow-
ing regression variables were used: BED, stage of disease,
male sex, study publication year, study size, allocation
concealment and handling of withdrawals. This meta-
analysis considered 14 published trials [14,16–22,24–
28]: it included the VASOG-I trial [14], which we
excluded, and it did not include a trial from Hungary [23]
or the single-fraction RT arm from the MRC-I trial [18]. All
comparisons were made using odds ratios. Camma et al.
[35] detected a significant reduction in overall mortality
with preoperative RT (Table 2). In a subgroup analysis, the
decrease in mortality occurred in patients with Dukes'
stages B and C but not in patients with stage A disease. No
interaction was found between RT dose and survival (BED
Meta-analysis examining preoperative RT for patients with resectable rectal cancer: postoperative morbidity Figure 5
Meta-analysis examining preoperative RT for patients with resectable rectal cancer: postoperative morbidity.
Table 2: Results of three meta-analyses of preoperative RT versus surgery alone in resectable rectal cancer.
Outcome Pooled Results Odds Ratio, 95% Confidence Interval and p value
Camma et al [35] CRCCG [36]* Present Review
Overall Mortality 0.84 (0.72, 0.98)
p = 0.03
0.95 (0.86, 1.06)
p = 0.34
0.85 (0.74, 0.97)
p = 0.019
Local Failure 0.49 (0.38, 0.62)
p < 0.001
0.58 (0.42, 0.80)
p = 0.00008
0.62 (0.45, 0.85)
p = 0.0029
30-day Postoperative Mortality 1.38 (0.86, 2.32)
p = 0.22
-
-
1.42 (0.90, 2.23)
p = 0.13
* ORs calculated from data shown in Figure 1[35].BMC Medicine 2003, 1 http://www.biomedcentral.com/1741-7015/1/1
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< 30 or > 30; p = 0.53). In the regression analysis none of
the factors used as variables had a significant impact on
survival. Cancer-specific mortality and local recurrences
were also reduced by the use of preoperative RT (Table 2)
but not distant metastases. The overall rate of post-opera-
tive adverse events was higher in patients receiving preop-
erative RT (57.4% versus 42.4%; p < 0.001). The 30-day
postoperative mortality was not significantly different
between patients receiving preoperative RT and those hav-
ing only surgery. Camma et al. [35] concluded that preop-
erative RT reduced overall and cancer-specific mortality
rates, and particularly local recurrence rates, while not
affecting distant metastases. Postoperative mortality was
not affected by the use of preoperative RT in spite of a
higher rate of adverse events in patients.
The Colorectal Cancer Collaborative Group (CCCG) [36]
identified trials of adjuvant preoperative and postopera-
tive RT started before January 1st, 1987. The CCCG search
yielded 19 trials of preoperative RT which included five
trials not included in our review: two trials using preoper-
ative plus postoperative RT [15,31], one trial including
patients with metastatic disease [14], another combining
RT with 5-fluorouracil (5-FU) administration [33] and a
Japanese trial published in 1989. Analysis was done by the
log-rank method for overall and disease-specific mortality
and for all and isolated recurrences. The overall yearly
death rate was 5.6% (standard error ± 3.3). All recurrences
and isolated recurrences were significantly decreased by
preoperative RT at 5 years (45.9% vs. 52.9% and 12.5%
vs. 22.2%, respectively) and at 10 years (55.1% vs. 60.8%
and 16.7% vs. 25.8%, respectively). There was significant
heterogeneity between the results of the 12 trials analyzed
(p = 0.002), which was explained by the greater efficacy of
RT at higher biologically effective doses (> 30 Gy). The
reduction in local recurrence was proportionally similar
for the various stages of the disease, and not affected by
either sex or age. A multivariate analysis was not done
[36].
The results of the published meta-analyses [35,36] and
the one conducted for this systematic review are shown in
Table 2.
Preoperative RT versus alternative treatments
Preoperative RT versus postoperative adjuvant RT in high-risk cases
In a multi-institutional randomized trial in Sweden,
patients with operable rectal cancer were randomized to
preoperative RT or selective postoperative RT if the patho-
logical stage was II or III [30,37]. Overall survival was the
same for both treatment groups. When only patients with
radical resection were considered, local recurrence was
less likely for those receiving preoperative RT (11% vs.
22%; p = 0.02) (Table 3). Postoperative complications,
both early [30] and late [37], were significantly more fre-
quent after higher-dose postoperative RT. The investiga-
tors emphasized that a short course of high fraction
preoperative RT is preferable to a standard course of
postoperative RT. Preoperative RT was better in reducing
local recurrence rates and was associated with lower
morbidity.
Table 3: Randomized trials of preoperative RT compared to alternative treatments in rectal cancer.
Trial (Reference) Treatment No. Patients Local Failure (%) Survival Rate 
at 5 years (%)
Preoperative RT Surgery Delay Postoperative RT 
(Delay)
Pahlman & Glimelius [30] 5.1 Gy × 5
-
1 week
-
-
60 Gy in 54*
(4–6 weeks)
236
235
22%
33%
p = 0.012
43%
37%
p = 0.43
RTOG [31] 0.5 Gy × 1
-
1 day
-
45–51 Gy*
(2–6 weeks)
175
178
32%
32%
p = NS
43%
32%
p = NS
Herrmann et al. [32] 3.3 Gy × 5
-
1–2 days
-
41.5 Gy in 48*
59.8 Gy in 56*
(6–14 weeks)
48
46
25%
39%
p = 0.142
49%
37%
p = NS
EORTC [33] 2.3 × 15
2.3 × 15
+ 5-FU
2 weeks
2 weeks
-
-
121
126
15%
15%
p = NS
59%
46%
p = 0.06
Francois et al. [34] 3.0 Gy × 13
3.0 Gy × 13
2 weeks
6–8 weeks
-
-
99
102
9%
9%
p = NS
78%†
73%†
p = NS
Note: NS indicates not statistically significant; RTOG, Radiation Therapy Oncology Group. * Radiation given only to high-risk cases (stages B2 and 
C). † 3-year survival rate.BMC Medicine 2003, 1 http://www.biomedcentral.com/1741-7015/1/1
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Two other randomized trials have investigated the benefit
of preoperative RT given to patients who also received
postoperative RT if the pathological stage was II or III
[31,32] (Table 3). In a study by the Radiation Therapy
Oncology Group (RTOG), investigators randomized
patients to a single dose of 5 Gy preoperatively and gave
45 Gy postoperatively to all high-risk patients [31]. After
more than five years of follow-up, survival and local fail-
ure were similar in patients with or without preoperative
RT. The preoperative RT dose in this trial was very small
and has been shown to be ineffective [17,18]. German
investigators performed a similar but smaller trial using a
higher preoperative RT dose [32]. Patients were
randomized to immediate surgery or to receive 16.5 Gy in
5 fractions preoperatively. After surgery, patients at high
risk of local recurrence (T4 stage, R1-2 or intraoperative
tumor perforation) also received 41.4 Gy if they had pre-
operative RT and 59.8 Gy if they did not have preoperative
RT. In a multivariate analysis of local recurrence, the only
significant variable was staging (International Union
Against Cancer [UICC]; p = 0.0003) while preoperative RT
and T4 stage had non-significant effects (p = 0.08 and
0.07, respectively). In a similar analysis of survival, three
variables were significant: age (p = 0.0003), UICC stage (p
= 0.001) and residual disease status (p = 0.01). Preopera-
tive RT had a non-significant effect (p = 0.078). These
trials [31,32] indicate that selective postoperative RT
annuls any potential positive effect of preoperative RT in
low dose.
Preoperative RT alone versus preoperative RT plus chemotherapy
An early randomized trial by the European Organization
for Research and Treatment of Cancer (EORTC) [33] com-
pared preoperative RT with or without chemotherapy. 5-
FU by bolus injection was given for four days during the
first week of the radiation course. The trial was marred by
many difficulties, with 27% of the cases being ineligible or
not evaluable. The combined treatment did not reveal any
advantage over RT alone (Table 3). Of interest was a
marginally significant decrease in liver metastases for
patients receiving preoperative combined treatment (p =
0.06).
Preoperative RT with surgery at different intervals
One trial by French investigators tested whether the delay
of surgery after the completion of preoperative RT is
important [34] (Table 3). Operable patients with rectal
tumors accessible to digital rectal examination (stage T2-
3, NX, M0) received preoperative RT (39 Gy in 13 frac-
tions over 17 days through 3 fields) and were randomized
to surgery after a short (two-week) or a long (six- to eight-
week) interval. The only significant difference in out-
comes, favoring the long over the short delay, was the
higher proportion of patients with a clinical tumor
response (partial plus complete) (53.1% versus 71.7%; p
= 0.007) and pathological downstaging (10.3% versus
26%; p = 0.005). The three-year local failure and survival
rates were not significantly different.
Discussion
Results of three meta-analyses (Table 2) indicate that pre-
operative RT compared to surgery alone significantly
decreases the risk of local failure and overall mortality.
The absolute reduction in local failure is 8.6% (95% CI,
3.1% to 14.2%) while the absolute reduction in overall
mortality at five years is 3.5% (95% CI, 1.1% to 6.0%).
Early results of the Dutch trial [38] confirm the decrease
in local recurrence with preoperative RT even after opti-
mal surgery with total mesorectal excision. The improved
results of recent trials can be explained by better patient
selection and radiation prescription. Swedish investiga-
tors, comparing the results of the Stockholm-I [25] and
Stockholm-II [29] trials of preoperative RT, showed that
the overall survival of patients is significantly affected by
the 60-day postoperative mortality rate [39]. This early
fatality rate is due to an excess of infectious, cardiovascu-
lar and thromboembolic causes. This excess in mortality is
attributed to the delivery of similar radiation doses to
larger versus smaller volumes and by two rather than mul-
tiple radiation portals, and to patient characteristics such
as evidence of ischemia by ECG and poor performance
status. An increase in morbidity was also observed and
consisted of venous thromboembolism, femoral neck and
pelvic fractures, and intestinal obstruction. A subgroup of
patients who participated in the Swedish trial [28] com-
pleted a questionnaire about anorectal dysfunction.
Bowel disturbances led to social restrictions in 30% of
patients who received preoperative RT compared with
10% of patients who received surgery alone (p < 0.01).
The abnormalities included more frequent bowel
movements, urgency and incontinence. No single factor
could be identified to explain the complications, but the
authors postulated the radiation effect on the anal sphinc-
ter itself or on its nerve supply [40]. Similar anorectal dys-
function has been reported after postoperative RT
combined with chemotherapy [41,42].
Preoperative RT in high fractions has been compared with
standard low-fraction postoperative adjuvant RT [30]. The
overall survival was the same for both treatment groups
but the local recurrence rate was lower and the morbidity
less for preoperative RT. While preoperative RT was given
to all cases, postoperative RT was given only to high-risk
cases (Dukes' stages B2 and C), a group equal to half the
number of cases treated with the preoperative approach.
The increased morbidity of the postoperative RT must be
related in part to the higher radiation dose given. In a ret-
rospective analysis of preoperative and postoperative RT
trials, Glimelius et al. [10] observed that for a similar
reduction in local failure the dose of radiation must beBMC Medicine 2003, 1 http://www.biomedcentral.com/1741-7015/1/1
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higher in the postoperative than in the preoperative
setting.
The use of preoperative RT in small doses did not decrease
the indications for postoperative adjuvant RT [31,32].
Patients who received four bolus injections of 5-FU during
the preoperative RT in one old trial increased postopera-
tive mortality and decreased overall survival [33]. The
cause for this toxicity is not known and has not been
observed in subsequent trials of combined therapy. The
delay of surgery after preoperative RT for more than two
weeks decreased the rate of stage III disease but had no
impact on resectability, local recurrence or survival [34].
Development of a clinical practice guideline
Gastrointestinal Cancer DSG consensus
When presented with the reviewed evidence, the discus-
sion of the Gastrointestinal Cancer DSG focused on
results from recent trials of preoperative RT in Europe that
demonstrated significant improvements in local failure
and survival rates. These results, achieved with a short
course of radiation (five fractions) and with less toxicity
than standard longer courses of radiation, have prompted
the widespread use of this treatment modality in Europe
and more recently in North America. Some treatment
centers in Ontario have started phase II studies of preop-
erative RT, in some cases with concurrent chemotherapy.
There are, however, some concerns about the widespread
use of preoperative RT. Some potential risks of the
treatment seem preventable. The use of radiation given to
smaller volumes and multiple fields, instead of the past
practice of two fields, has been shown to decrease both
early postoperative morbidity and mortality [25,28,29].
The exclusion of patients with poor performance status
and those with ischemic changes in the electrocardiogram
(ECG) [39] reduced both mortality and morbidity in the
first two months. More difficult to predict is the long-term
anorectal dysfunction, which restricts the social life of one
third of survivors in some series following both preopera-
tive and postoperative adjuvant RT [40,42]. Another con-
cern is that some of the preoperatively irradiated patients
would not have required this treatment based on the post-
operative staging of the disease. Furthermore, the prog-
nostic value of the postoperative staging of irradiated
patients remains uncertain, although downstaging does
not occur after the short course of preoperative RT. The
postoperative pathological staging is important to deter-
mine the need for adjuvant chemotherapy, which
improves survival and reduces local recurrence [4].
Should preoperative RT be recommended for adjuvant
treatment in resectable rectal cancer? The common prac-
tice in North America for patients with resected stages II
and III rectal cancer has been postoperative RT plus
chemotherapy. In a previous guideline, it was demon-
strated that this combined treatment significantly reduced
local failure by 50% (95% CI, 8% to 73%) and improved
patient survival by 42% (95% CI; 8% to 63%) for patients
with stage II and III rectal cancer when compared to post-
operative RT alone [4]. In similar patients, postoperative
RT alone compared to observation after surgery decreased
local recurrences by 27% (95% CI, 4% to 45%) but did
not improve survival. Postoperative RT alone has been,
therefore, discouraged [4]. Preoperative RT alone, when
compared to surgery, has been shown to decrease local
failure by approximately 50% and to improve survival by
approximately 15% (Table 2). The improvement in local
recurrence has occurred after optimal surgery with TME
[38]. In a single trial [30,37], preoperative short-course RT
has induced less local recurrence (11% versus 22%; p =
0.02) and less morbidity than conventional postoperative
RT alone. From these results it can be inferred that preop-
erative RT is a better treatment choice than postoperative
RT with less local failures and less morbidity. A compari-
son of preoperative RT followed by postoperative chemo-
therapy versus combined postoperative RT plus
chemotherapy is presently being investigated in clinical
trials but mature results are not yet available for review.
Based on the evidence from the Swedish and Dutch trials
[28,38] and the meta-analyses data, preoperative RT (fol-
lowed by chemotherapy for at least patients with stage III)
is an alternative to our previous recommendation for
combined postoperative RT plus chemotherapy for
resected patients with stage II and III rectal cancer.
Patients must be made aware of the potential benefits and
drawbacks of both approaches. Benefits of short-course
preoperative RT are lower local failure and less treatment
morbidity. Local failure is an important outcome in rectal
cancer as recurrences are associated with significant disa-
bility. Drawbacks are the need to use preoperative RT in
more patients compared to RT administered according to
postoperative staging and the possibility that patients not
requiring radiation may develop treatment associated
complications.
Physicians should encourage patients to participate in
clinical trials of the primary treatment of rectal cancer.
These trials should require the best possible surgery, the
confirmation of the accuracy of clinical staging versus
pathological staging, and the use of measures of quality of
life. Patients must also be clearly advised of the differences
between treatment approaches.
External review
Practitioner feedback was obtained through a mailed sur-
vey. The survey consisted of items evaluating the methods,
results, and interpretive summary used to inform the draft
recommendations and whether the draft recommenda-BMC Medicine 2003, 1 http://www.biomedcentral.com/1741-7015/1/1
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tions should be approved as a practice guideline. Written
comments were invited. Follow-up reminders were sent at
two weeks (post card) and four weeks (complete package
mailed again). The Gastrointestinal Cancer DSG reviewed
the results of the survey.
1. Number surveyed: 155 practitioners in Ontario (30
medical oncologists, 21 radiation oncologists, 100 sur-
geons, and four gastroenterologists).
2. Return rate: 63%
3. Written comments attached: 54%
4. Agreement with the summary of the evidence: 87%
5. Agreement with the recommendation: 85%
6: Approval of the recommendation as a practice guide-
line: 68%
Summary of main findings
Written comments provided by practitioners varied. Sev-
eral respondents expressed concern with the statement in
the draft recommendations that "Postoperative
radiotherapy for patients with stage II / III rectal cancer is
as effective in prolonging survival as preoperative radio-
therapy for all rectal cancer patients regardless of stage of
disease". These respondents noted that preoperative ver-
sus postoperative RT was not the topic of this guideline
and randomized trials addressing this issue are still
ongoing.
Other respondents also questioned the recommendation
that "postoperative radiotherapy combined with chemo-
therapy should remain the standard treatment". They
argued that if the results of the on-going trials demon-
strate that preoperative and postoperative RT are equally
effective, then one treatment should not be recommended
over the other as the standard treatment. Several respond-
ents raised the question of the role of total mesorectal
excision.
Modifications or actions
Practitioner feedback indicated a need to clarify the role of
preoperative RT in the context of the companion
guideline [4] recommending postoperative RT plus chem-
otherapy for stage II and III rectal cancer. In this context,
the magnitude of benefits and drawbacks of preoperative
and postoperative RT with and without chemotherapy are
further discussed in the Gastrointestinal Cancer DSG Con-
sensus section.
Practice guidelines coordinating committee approval process
The guideline was circulated to 11 members of the Prac-
tice Guideline Coordinating Committee. Seven members
returned ballots; five approved the guideline report as
written, and two members approved the guideline condi-
tional on the Gastrointestinal Cancer DSG addressing sug-
gestions for revision. The suggestions referred to the
recommendations and the meta-analyses. Changes were
made to the guideline based on these suggestions, and a
revised version was resubmitted to the PGCC for further
consideration. The practice guideline was approved with
one dissenting vote.
Conclusions
This practice guideline reflects the integration of a review
of the evidence, the Gastrointestinal Cancer DSG draft rec-
ommendations and the feedback obtained from the exter-
nal review process. It has been approved by the
Gastrointestinal Cancer DSG and the Practice Guidelines
Coordinating Committee.
Target population
These recommendations apply to adult patients with clin-
ically resectable rectal cancer. This report does not con-
sider the use of preoperative RT to convert locally
advanced, initially unresectable rectal cancer to resectable
cases, to preserve the anal sphincter, or to delay the need
for colostomy.
Recommendations
Preoperative RT is an acceptable alternative to the previ-
ous practice of postoperative RT for patients with stage II
and III resectable rectal cancer.
Both preoperative and postoperative RT decrease local
recurrence but neither improves survival as much as post-
operative RT combined with chemotherapy. Therefore, if
preoperative RT is used, chemotherapy should be added
postoperatively to at least patients with stage III disease.
Qualifying statement
Patients must be made aware of the potential benefits and
drawbacks of both approaches. Benefits of short-course
preoperative RT are lower local failure and less treatment
morbidity. Local failure is an important outcome in rectal
cancer as recurrences are associated with significant disa-
bility. Drawbacks are the need to use preoperative RT in
more patients compared to RT administered according to
postoperative staging and the possibility that patients not
requiring radiation may develop treatment associated
complications.
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